Key facts
- RobotDreams’s last known valuation is $11.3M (Feb 2026).
- It has raised $3.3M; the latest was Angel (individual) ($590K) in Feb 2026.
- Notable investors include Plug and Play Tech Center, STARTPLATZ, Austria Wirtschaftsservice, AXOLOTL (Germany), Scale-up Champions — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for RobotDreams
- ·The full record, as it builds
Funding rounds
No funding rounds for RobotDreams are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RobotDreams
Developer of artificial intelligence (AI)-based diagnostic software designed for the analysis of hematological data to identify physiological conditions in clinical settings. The company's platform utilizes modular, deep learning-powered models that process blood samples without requiring electrocardiogram (ECG) or cardiac biomarker data, enabling healthcare providers to accelerate risk assessment, improve diagnostic accuracy, reduce unnecessary hospital admissions, and detect acute cardiovascular conditions, such as heart attacks, using only the first available blood sample.
- Sector
- Healthcare
- HQ
- Graz, Austria
- Founded
- 2019
- Employees
- 8
- Website
- robotdreams.co/
- Ownership
- Privately Held (backing)
RobotDreams doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RobotDreams shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RobotDreams in its N-PORT filings yet. We sweep new filings monthly.